-
Internal medicine journal · Feb 2011
Review Case ReportsRituximab-induced serum sickness in refractory immune thrombocytopenic purpura.
- G Le Guenno, M Ruivard, L Charra, and P Philippe.
- Department of Internal Medicine, Hotel-Dieu, CHU, Clermont-Ferrand, France. gleguenno@chu-clermontferrand.fr
- Intern Med J. 2011 Feb 1; 41 (2): 202-5.
AbstractSerum sickness may occur in patients treated with chimeric monoclonal antibody. Rituximab, an anti-CD20 chimeric monoclonal antibody, is used with increasing frequency in chronic immune thrombocytopenic purpura (ITP). Rituximab is relatively safe; however, serum sickness is reported in 1-20% of patients, more commonly among those with autoimmune conditions. We describe a case of serum sickness in a patient with ITP and review the literature of rituximab-induced serum sickness.© 2011 The Authors. Internal Medicine Journal © 2011 Royal Australasian College of Physicians.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..